Age: 41.0
Sex: M
Vaccine: MENB, MENB, MENB, MNQ, MNQ, PPV
Symptoms: Extra dose administered, Infection, Product administered to patient of inappropriate age, Vitamin D deficiency
Clinical narrative: infectious disease; Vitamin D deficiency; on 06/06/2019: Menveo and on 12/6/2019: Menveo; On 12/6/2019 received Bexsero; On 10/22/2019 received Bexsero; This non-serious case was reported by a physician via other manufacturer and described the occurrence of infection in a 41-year-old male patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included Men B NVS (Bexsero) for prophylaxis, Men ACWY-CRM NVS (Menveo) for prophylaxis, Men ACWY-CRM NVS (Menveo) for prophylaxis, Meningococcal vaccine B rfHbpA/fHbpB (Trumenba) for prophylaxis and Pneumococcal vaccine for prophylaxis.   On 06-DEC-2019, the patient received the 2nd dose of Bexsero. On 22-OCT-2019, the patient received the 1st dose of Bexsero. On 06-DEC-2019, the patient received the 2nd dose of Menveo. On 06-JUN-2019, the patient received the 1st dose of Menveo and Trumenba. On 22-OCT-2019, the patient received Pneumococcal vaccine. On 22-OCT-2019, not applicable after receiving Bexsero, Menveo and Menveo, an unknown time after receiving Bexsero and not applicable after receiving Bexsero, Menveo and Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: On 10/22/2019 received Bexsero). On 06-DEC-2019, the patient experienced extra dose administered (Verbatim: on 06/06/2019: Menveo and on 12/6/2019: Menveo) and inappropriate age at vaccine administration (Verbatim: On 12/6/2019 received Bexsero). On an unknown date, the patient experienced infection (Verbatim: infectious disease) and vitamin d deficiency (Verbatim: Vitamin D deficiency). Bexsero was discontinued. The outcome of the infection and vitamin d deficiency were not reported and the outcome of the extra dose administered, inappropriate age at vaccine administration and inappropriate age at vaccine administration were unknown.   It was unknown if the reporter considered the infection and vitamin d deficiency to be related to Bexsero, Bexsero Pre-Filled Syringe Device, Bexsero, Bexsero Pre-Filled Syringe Device, Menveo and Menveo.     It was unknown if the company considered the infection and vitamin d deficiency to be related to Bexsero, Bexsero Pre-Filled Syringe Device, Bexsero, Bexsero Pre-Filled Syringe Device, Menveo and Menveo.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 12-SEP-2024 The patient was up-to date-on vaccinations. The reporter again discussed the possibility of prophylactic antibiotics, and he did see infectious disease. He would like to forego that at this time. The patient had vitamin D deficiency. The patient received Bexsero 2 doses above than the recommended age limit, which led to inappropriate age at vaccine administration. The patient received 2nd dose of Menveo, which led to extra dose administered. It was unknown if the reporter considered the infection and vitamin d deficiency to be related to Trumenba and Pneumococcal vaccine. Note: Event occurrence time was not known, hence due to limited information all doses of the vaccines captured as suspect conservatively.